Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 6/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | EDNRB | P24530 | 2/20 | 0.42 |
| ▸ | EDNRA | P25101 | 2/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | CPT1A | P50416 | 1/20 | 0.40 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL6851222 | 0.91 | MAPT (0.44) | MAPTMAPK10PPARGFABP4SIGMAR1 | |
| SCHEMBL7110258 | 0.88 | PPARG (0.45) | MAPTMAPK10PPARGALDH1A1MEN1 | |
| SCHEMBL24482671 | 0.81 | MAPT (0.53) | MAPTMAPK10PPARGFABP4PTGER4 | |
| SCHEMBL6855595 | 0.78 | MAPT (0.48) | MAPTMAPK10PPARGFABP4FEN1 | |
| SCHEMBL7035422 | 0.76 | PPARG (0.53) | MAPTMAPK10PPARGFABP4EDNRB | |
| SCHEMBL27581403 | 0.75 | PPARG (0.53) | MAPTMAPK10PPARGFABP4EDNRB | |
| SCHEMBL27580260 | 0.75 | PPARG (0.53) | MAPTMAPK10PPARGFABP4EDNRB | |
| SCHEMBL7039948 | 0.75 | PPARG (0.59) | MAPTMAPK10PPARGFABP4EDNRB | |
| SCHEMBL6300362 | 0.75 | MAPT (0.57) | MAPTMAPK10PPARGFABP4FEN1 | |
| SCHEMBL24482780 | 0.75 | CCR2 (0.65) | MAPTMAPK10PPARGFABP4PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787651-B2 | 2-CARBOXY-SUBSTITUTED; TREATING OSTEOPENIA, OSTEOPOROSIS, CANCER, DIABETES AND ATHEROSCLEROSIS. | SMITHKLINE BEECHAM CORPORATION | 2004-09-07 | — | — | US | disclosed |
| EP-1341761-A1 | SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-$g(g) BINDING AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
| WO-2002030895-A1 | SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | PPARG, PPARA, PPARD | MAPT 3447/4885MAPK10 1496/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.